Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
ABO blood group barrier in allogeneic bone marrow transplantation revisited.
Seebach JD, Stussi G, Passweg JR, Loberiza FR Jr, Gajewski JL, Keating A, Goerner M, Rowlings PA, Tiberghien P, Elfenbein GJ, Gale RP, van Rood JJ, Reddy V, Gluckman E, Bolwell BJ, Klumpp TR, Horowitz MM, Ringdén O, Barrett AJ; GVHD Working Committee of Center for International Blood and Marrow Transplant Research. Seebach JD, et al. Biol Blood Marrow Transplant. 2005 Dec;11(12):1006-13. doi: 10.1016/j.bbmt.2005.07.015. Biol Blood Marrow Transplant. 2005. PMID: 16338623 Free article.
A total of 3103 patients with early-stage leukemia who underwent transplantation between 1990 and 1998 with bone marrow from an HLA-identical sibling and who were reported to the Center for International Blood and Marrow Transplant Research were studied. ...There was no ev …
A total of 3103 patients with early-stage leukemia who underwent transplantation between 1990 and 1998 with bone marrow from an HLA-i …
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL, Sobocinski KA, Horowitz MM; Chronic Leukemia Working Committee, Center for International Blood and Marrow Transplant Research. Giralt SA, et al. Br J Haematol. 2007 Jun;137(5):461-7. doi: 10.1111/j.1365-2141.2007.06582.x. Epub 2007 Apr 24. Br J Haematol. 2007. PMID: 17459051 Free article.
The discovery and approval of imatinib drastically changed the therapeutic algorithm for chronic myeloid leukaemia (CML). Imatinib is now considered the therapy of choice for patients with newly diagnosed CML, including those previously considered candidates for all …
The discovery and approval of imatinib drastically changed the therapeutic algorithm for chronic myeloid leukaemia (CML). Imat …